Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Assembly Biosciences (ASMB) Invested Capital: 2015-2025

Historic Invested Capital for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to $182.7 million.

  • Assembly Biosciences' Invested Capital rose 602.59% to $182.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $182.7 million, marking a year-over-year increase of 602.59%. This contributed to the annual value of $33.4 million for FY2024, which is 18.83% down from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Invested Capital is $182.7 million, which was up 909.36% from $18.1 million recorded in Q2 2025.
  • Assembly Biosciences' 5-year Invested Capital high stood at $247.2 million for Q1 2021, and its period low was $18.1 million during Q2 2025.
  • Its 3-year average for Invested Capital is $51.2 million, with a median of $34.7 million in 2024.
  • As far as peak fluctuations go, Assembly Biosciences' Invested Capital slumped by 59.27% in 2023, and later soared by 602.59% in 2025.
  • Assembly Biosciences' Invested Capital (Quarterly) stood at $168.9 million in 2021, then crashed by 51.07% to $82.7 million in 2022, then plummeted by 50.28% to $41.1 million in 2023, then dropped by 18.83% to $33.4 million in 2024, then skyrocketed by 602.59% to $182.7 million in 2025.
  • Its last three reported values are $182.7 million in Q3 2025, $18.1 million for Q2 2025, and $27.1 million during Q1 2025.